Pressemeldinger Se alle 21 treff

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

Pressemeldinger   •   17-06-2014 13:58 CEST

− DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate – − Positive Results Set Stage for Regulatory Filings –

BIOGEN IDEC ANNOUNCES OFFICIAL PARTNERSHIP WITH SAILING SCLEROSIS’ “OCEANS OF HOPE” TO GLOBALLY CHANGE PERCEPTIONS OF MS

BIOGEN IDEC ANNOUNCES OFFICIAL PARTNERSHIP WITH SAILING SCLEROSIS’ “OCEANS OF HOPE” TO GLOBALLY CHANGE PERCEPTIONS OF MS

Pressemeldinger   •   28-05-2014 10:51 CEST

- Global Project Uses Sailing to Empower People Living with Multiple Sclerosis -

CHMP ADOPTS POSITIVE OPINION FOR PLEGRIDYTM (PEGINTERFERON BETA-1A) AS A TREATMENT FOR MULTIPLE SCLEROSIS IN THE EUROPEAN UNION

CHMP ADOPTS POSITIVE OPINION FOR PLEGRIDYTM (PEGINTERFERON BETA-1A) AS A TREATMENT FOR MULTIPLE SCLEROSIS IN THE EUROPEAN UNION

Pressemeldinger   •   28-05-2014 10:41 CEST

– European Commission Decision on Marketing Authorization Anticipated in 2H of 2014 – – PLEGRIDY May Offer People with MS a Combination of Efficacy, Favorable Safety Profile and Low Frequency Dosing Schedule –

Ny MS-pille godkjent til norske pasienter

Ny MS-pille godkjent til norske pasienter

Pressemeldinger   •   03-03-2014 10:06 CET

Statens legemiddelverk (SLV) har nå godkjent TECFIDERA® (dimetylfumarat), en ny bremsemedisin i kapselform, mot attakkvis multippel sklerose (MS). Bioteknologiselskapet Biogen Idec bekrefter at medikamentet vil være tilgjengelig på norske apotek allerede fra 1.mars.

Bilder 2 treff

Oppskaket dame

Oppskaket dame

Lisens Creative Commons navngivelse
Last ned
Størrelse

6.82 KB • 43 x 63 px

Mann på benk

Mann på benk

Lisens Creative Commons navngivelse
Last ned
Størrelse

2.27 MB • 3866 x 2577 px

Dokumenter 2 treff

Biogen Idec Pipeline

Biogen Idec Pipeline

Dokumenter   •   06-05-2011 14:31 CEST

BIIB image

BIIB image

Dokumenter   •   06-05-2011 14:31 CEST

Kontaktpersoner 1 treff

  • Pressekontakt
  • Medisinsk sjef
  • MS-nevrologi
  • glenn.gundersen@biogenidec.com
  • 95229513
  • 23005254
Medisinsk ansvarlig for Biogen Idec's legemiddel portefølje, klinisk forskning og regulatoriske oppgaver

You haven't completed the steps for your Hosted Newsroom

You haven't entered a correct link to your helper.html file for your Hosted Newsroom. Go to Publish and complete the steps.